Chugai hasn’t told us about sell-off: Amrad CEO
21 June, 2004 by Renate KrelleAmrad (ASX:AML) has not received specific instructions from Japanese drugmaker Chugai that it intends to sell of its 9 per cent stake in Amrad, CEO Peter Smith said today.
News: QIMR researchers aim for EBV vaccine
21 June, 2004 by Graeme O'NeillResearchers at the Queensland Institute for Medical Research (QIMR) in Brisbane hope to begin human trials late this year of a vaccine that could prevent three different forms of cancer associated with infection by Epstein-Barr virus.
News: Pox researchers point to bioterrorism solutions
21 June, 2004 by Susan WilliamsonThe way certain cytokines regulate the immune response to mousepox has potential to help with poxvirus infections, including smallpox, according to new research at the ANU.
7th World Biomaterials Congress: Take heart from new research
21 June, 2004 by Susan WilliamsonOne of the highlights of the 7th World Biomaterials Congress was the presentation by plenary speaker Prof Sir Magdi Yacoub, from the Imperial College London, Heart Science Centre in the UK, brought to Australia by Sydney-based company Ventracor.
Fonterra cuts won't hurt us: ViaLactia CEO
18 June, 2004 by Graeme O'NeillNew Zealand dairy cooperative Fonterra this week announced that it was to cut research funds to its biotechnology subsidiary ViaLactia by 40 per cent -- about NZ$5 million. But ViaLactia CEO Dr Colin South said the impact of the cuts within NZ would be minimal.
Chemeq drug helps pigs gain weight in trial
18 June, 2004 by Renate KrelleChemeq’s polymeric antimicrobial has proved itself in a NZ trial of 584 21-day old weaner pigs, improving average daily weight gain, feed conversion and disease control.
EvoGenix partners with Canada's Viventia
18 June, 2004 by Iain ScottBusiness activity at EvoGenix continues apace -- the unlisted Sydney company announced today that itwould team up with Canadian biotech Viventia to identify antibodies as cancer therapeutics.
Genzyme aims to sell thyroid test as treatment
17 June, 2004 by Staff WritersGenzyme aims to file for marketing approval this year for a therapy to reduce the side-effects of thyroid cancer treatment.
Peptech investees pick up grant and knighthood
17 June, 2004 by Renate KrelleThe day after Peptech (ASX: PTD) celebrated the knighting of its investee company Domantis’ co-founder Dr Gregory Winter, its joint venture partner Biosceptre International was tapped for a $2.1 million START grant to develop a skin cancer therapeutic.
Novogen establishes Australian site for breast cancer study
16 June, 2004 by Graeme O'NeillThe Royal Women’s Hospital in Melbourne has been announced as one of two international sites for a phase II clinical trial of phenoxodiol, the promising chemotherapy-boosting compound phenoxodiol, developed by Marshall Edwards (LSE AIM: MSH, NASDAQ:MSHL), a US subsidiary of Sydney pharmaceutical company Novogen (ASX: NRT, NASDAQ: NVGN).
BIO 2004: Best is yet to come, industry heavyweights predict
16 June, 2004 by Melissa TrudingerFour industry visionaries provided a glimpse of the biotechnology industry's future at the final plenary session of BIO 2004, which wrapped up in San Francisco last week.
Antisense eagerly awaits MS therapy result
15 June, 2004 by Renate KrelleAs Biogen Idec and Elan await approval from the FDA and the European Medicines Agency for their multiple sclerosis therapeutic, Antegren, Melbourne-based Antisense Therapeutics (ASX:ANP) will also be watching with bated breath.
CSIRO halves GroPep investment
15 June, 2004 by Renate KrelleThe CSIRO -- formerly the largest shareholder in Adelaide-based biopharma GroPep (ASX:GRO) -- last week halved its shareholding in the company, selling 5 million shares valued at just under $3.5 million.
GTG firms up O'Connor partnership
15 June, 2004 by Graeme O'NeillGenetic Technologies (ASX:GTG) has sealed its broad strategic alliance with Perth-based biotech research agency, the CY O'Connor ERADE Village Foundation (CYO), foreshadowed in October last year.
C3 signs Italian distributor
11 June, 2004 by Renate KrellePerth-based tissue engineering company Clinical Cell Culture (C3, ASX:CCE) has signed Rome-based Health Defence to distribute its CellSpray and ReCell products in Italy.
